It appears you don't have support to open PDFs in this web browser. To view this file, Open with your PDF reader
Abstract
The strong antibacterial, antiviral and anticancer activities demonstrated by quinolones make them promising lead structures and important synthetic targets for drug discovery. Here, we report, to the best of our knowledge, the first scalable total synthesis of antiviral (+)-aniduquinolone A, possessing a 3,4-dioxygenated 5-hydroxy-4-aryl-quinolin-2(1H)-one skeleton. This synthetic strategy explores E-stereoselective Horner–Wadsworth–Emmons (HWE) olefination as the key step to assemble isopropenyl substituted tetrahydrofuran onto the 3,4-dioxygenated 5-hydroxy-4-aryl-quinolin-2(1H)-one core, which is built by highly diastereoselective intramolecular aldol reaction. Moreover, two sets of stereoisomers of aniduquinolone A with substantially overlapping NMR data were synthesized completely and assigned unambiguously by comprehensive analysis of both their spectroscopic and X-ray diffraction data. Unexpectedly, aflaquinolones A, C, and D that feature different 2,4-dimethyl cyclohexanone moieties were transformed successfully from (+)-aniduquinolone A by treating with TFA. The methodology delineated herein can be applied broadly to the synthesis of natural alkaloids containing the core structure of 3,4-dioxygenated 5-hydroxy-4-aryl-quinolin-2(1H)-one.
Quinolones can possess desirable antibacterial, antiviral and anticancer properties, rending them important synthetic targets for drug discovery purposes. Here, the gram-scale total synthesis of antiviral (+)-aniduquinolone A, possessing a 3,4-dioxygenated 5-hydroxy-4-aryl-quinolin-2(1H)-one skeleton, is reported, as well as its acid-catalyzed rearrangement to aflaquinolones A, C, and D.
You have requested "on-the-fly" machine translation of selected content from our databases. This functionality is provided solely for your convenience and is in no way intended to replace human translation. Show full disclaimer
Neither ProQuest nor its licensors make any representations or warranties with respect to the translations. The translations are automatically generated "AS IS" and "AS AVAILABLE" and are not retained in our systems. PROQUEST AND ITS LICENSORS SPECIFICALLY DISCLAIM ANY AND ALL EXPRESS OR IMPLIED WARRANTIES, INCLUDING WITHOUT LIMITATION, ANY WARRANTIES FOR AVAILABILITY, ACCURACY, TIMELINESS, COMPLETENESS, NON-INFRINGMENT, MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE. Your use of the translations is subject to all use restrictions contained in your Electronic Products License Agreement and by using the translation functionality you agree to forgo any and all claims against ProQuest or its licensors for your use of the translation functionality and any output derived there from. Hide full disclaimer
Details


1 Ocean University of China, Key Laboratory of Marine Drugs, The Ministry of Education of China, School of Medicine and Pharmacy, Qingdao, China (GRID:grid.4422.0) (ISNI:0000 0001 2152 3263); Pilot National Laboratory for Marine Science and Technology (Qingdao), Laboratory for Marine Drugs and Bioproducts, Qingdao, China (GRID:grid.484590.4) (ISNI:0000 0004 5998 3072)
2 Ocean University of China, Key Laboratory of Marine Drugs, The Ministry of Education of China, School of Medicine and Pharmacy, Qingdao, China (GRID:grid.4422.0) (ISNI:0000 0001 2152 3263); Yantai University, School of Pharmacy, Yantai, China (GRID:grid.440761.0) (ISNI:0000 0000 9030 0162)
3 Ocean University of China, Key Laboratory of Marine Drugs, The Ministry of Education of China, School of Medicine and Pharmacy, Qingdao, China (GRID:grid.4422.0) (ISNI:0000 0001 2152 3263)
4 Hainan Normal University, College of Chemistry and Chemical Engineering, Haikou, China (GRID:grid.440732.6) (ISNI:0000 0000 8551 5345)
5 Syngenta Jealott’s Hill International Research Centre, Bracknell, UK (GRID:grid.426114.4) (ISNI:0000 0000 9974 7390)